Royce & Associates LP Sells 93,226 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Royce & Associates LP lowered its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 9.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 879,627 shares of the company's stock after selling 93,226 shares during the quarter. Royce & Associates LP owned approximately 0.60% of MiMedx Group worth $8,462,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Disciplined Growth Investors Inc. MN grew its holdings in MiMedx Group by 0.8% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company's stock valued at $2,100,000 after buying an additional 2,737 shares in the last quarter. SkyView Investment Advisors LLC grew its holdings in shares of MiMedx Group by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the company's stock valued at $77,000 after purchasing an additional 3,000 shares in the last quarter. Principal Financial Group Inc. lifted its position in MiMedx Group by 6.3% during the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock valued at $328,000 after purchasing an additional 3,292 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of MiMedx Group by 0.7% in the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company's stock worth $4,849,000 after buying an additional 3,300 shares in the last quarter. Finally, Orion Capital Management LLC increased its holdings in shares of MiMedx Group by 46.3% in the 3rd quarter. Orion Capital Management LLC now owns 11,700 shares of the company's stock worth $69,000 after buying an additional 3,700 shares during the last quarter. Institutional investors own 79.15% of the company's stock.

Remove Ads

MiMedx Group Trading Down 0.4 %

NASDAQ MDXG traded down $0.03 during trading on Friday, hitting $7.94. The stock had a trading volume of 1,166,285 shares, compared to its average volume of 693,781. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The stock has a 50 day simple moving average of $8.37 and a 200 day simple moving average of $7.85. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of 14.44 and a beta of 1.97. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million during the quarter, compared to analysts' expectations of $89.42 million. Sell-side analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.

Insider Activity at MiMedx Group

In other news, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $430,762.44. Following the transaction, the chief accounting officer now owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. This represents a 11.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares of the company's stock, valued at $2,452,496.04. The trade was a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock worth $1,130,312 in the last 90 days. 1.30% of the stock is owned by corporate insiders.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.